RBC Capital analyst Douglas Miehm raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $9.00 (from $8.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Aurinia Pharmaceuticals (AUPH) 2600 contracts of January 12 calls trade as share price up 13%November 7, 2024 2:04 PM Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 8cNovember 7, 2024 9:08 AM Form 10-Q Aurinia Pharmaceuticals For: Sep 30November 7, 2024 6:22 AM Form 8-K Aurinia Pharmaceuticals For: Nov 07November 7, 2024 6:14 AM Aurinia Pharmaceuticals (AUPH) Announces Board ChangesNovember 7, 2024 6:10 AM Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of GrowthNovember 7, 2024 6:10 AM Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 8c ; Offers GuidanceNovember 7, 2024 6:02 AM Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 DevelNovember 7, 2024 6:00 AM